---
annotation-target: 13756_2020_Article_706.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-29T02:42:56.837Z","updated":"2022-08-29T02:42:56.837Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":54,"end":93},{"type":"TextQuoteSelector","exact":"carbapenem-resistant Enterobacteriaceae","prefix":"fferent screening frequencies of","suffix":" inpatients undergoing hematopoi"}]}]}
>```
>%%
>*%%PREFIX%%fferent screening frequencies of%%HIGHLIGHT%% ==carbapenem-resistant Enterobacteriaceae== %%POSTFIX%%inpatients undergoing hematopoi*
>%%LINK%%[[#^rj9c5my16ln|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rj9c5my16ln


>%%
>```annotation-json
>{"created":"2022-08-29T02:49:06.583Z","updated":"2022-08-29T02:49:06.583Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":4918,"end":5244},{"type":"TextQuoteSelector","exact":" The overall inci-dence of BSIs caused by CRE in HSCT recipients is ap-proximately 1.8–2%. Due to the lack of effective antibiotictreatment, the death rate of CRE BSIs after HSCT is high(51–65%) [3, 6, 9, 10]. Increasing studies have revealed theimportance of preemptive intervention in the preventionand treatment of CRE BSIs","prefix":"ll transplantation (HSCT) [3–8].","suffix":".Gut colonization by CRE is an i"}]}]}
>```
>%%
>*%%PREFIX%%ll transplantation (HSCT) [3–8].%%HIGHLIGHT%% ==The overall inci-dence of BSIs caused by CRE in HSCT recipients is ap-proximately 1.8–2%. Due to the lack of effective antibiotictreatment, the death rate of CRE BSIs after HSCT is high(51–65%) [3, 6, 9, 10]. Increasing studies have revealed theimportance of preemptive intervention in the preventionand treatment of CRE BSIs== %%POSTFIX%%.Gut colonization by CRE is an i*
>%%LINK%%[[#^352afyebf5t|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^352afyebf5t


>%%
>```annotation-json
>{"created":"2022-08-29T02:51:47.242Z","updated":"2022-08-29T02:51:47.242Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":6930,"end":7320},{"type":"TextQuoteSelector","exact":" we implemented singleCRE rectal screening within 1 week before transplant-ation. From July 2018 to April 2019 (period 2), to im-prove the positive detection rate, we implementedcontinuous weekly screening until hematopoietic recon-struction. CRE screening would be repeated in patientswho had fever or underwent gut complications, such asabdominal pain, diarrhea and perianal inflammation.","prefix":"ber2017 to June 2018 (period 1),","suffix":"Data retrospectively collected f"}]}]}
>```
>%%
>*%%PREFIX%%ber2017 to June 2018 (period 1),%%HIGHLIGHT%% ==we implemented singleCRE rectal screening within 1 week before transplant-ation. From July 2018 to April 2019 (period 2), to im-prove the positive detection rate, we implementedcontinuous weekly screening until hematopoietic recon-struction. CRE screening would be repeated in patientswho had fever or underwent gut complications, such asabdominal pain, diarrhea and perianal inflammation.== %%POSTFIX%%Data retrospectively collected f*
>%%LINK%%[[#^sf05tvvj0qp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sf05tvvj0qp


>%%
>```annotation-json
>{"created":"2022-08-29T02:52:21.606Z","updated":"2022-08-29T02:52:21.606Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":10226,"end":10485},{"type":"TextQuoteSelector","exact":"Continuous vari-ables were evaluated using the Kruskal-Wallis test; cat-egorical variables were evaluated with Fisher’s exact testor Pearson chi square test. All tests and P-values weretwo-sided, and a P-value < 0.05 was considered statisti-cally significant.","prefix":"c., IBM Co., Chicago, IL, USA). ","suffix":"ResultsPatient characteristicsA "}]}]}
>```
>%%
>*%%PREFIX%%c., IBM Co., Chicago, IL, USA).%%HIGHLIGHT%% ==Continuous vari-ables were evaluated using the Kruskal-Wallis test; cat-egorical variables were evaluated with Fisher’s exact testor Pearson chi square test. All tests and P-values weretwo-sided, and a P-value < 0.05 was considered statisti-cally significant.== %%POSTFIX%%ResultsPatient characteristicsA*
>%%LINK%%[[#^ke3ipmnyjhk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ke3ipmnyjhk


>%%
>```annotation-json
>{"created":"2022-08-29T02:53:35.370Z","updated":"2022-08-29T02:53:35.370Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":12656,"end":12681},{"type":"TextQuoteSelector","exact":"Underlying disease, N (%)","prefix":"06(54.4)Female 85(42.5) 89(45.6)","suffix":" 0.208AML 78(39.0) 66(33.8)ALL 6"}]}]}
>```
>%%
>*%%PREFIX%%06(54.4)Female 85(42.5) 89(45.6)%%HIGHLIGHT%% ==Underlying disease, N (%)== %%POSTFIX%%0.208AML 78(39.0) 66(33.8)ALL 6*
>%%LINK%%[[#^bcn8qkhulmh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^bcn8qkhulmh


>%%
>```annotation-json
>{"created":"2022-08-29T02:53:40.725Z","updated":"2022-08-29T02:53:40.725Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":12811,"end":12831},{"type":"TextQuoteSelector","exact":"Type of HSCT, N (%) ","prefix":"0) 20(10.3)others 9(4.5) 14(7.2)","suffix":"0.697AllogeneicMUD 13(6.5) 14(7."}]}]}
>```
>%%
>*%%PREFIX%%0) 20(10.3)others 9(4.5) 14(7.2)%%HIGHLIGHT%% ==Type of HSCT, N (%)== %%POSTFIX%%0.697AllogeneicMUD 13(6.5) 14(7.*
>%%LINK%%[[#^ww1wlfiz64|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ww1wlfiz64


>%%
>```annotation-json
>{"created":"2022-08-29T02:54:01.166Z","updated":"2022-08-29T02:54:01.166Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":12537,"end":12544},{"type":"TextQuoteSelector","exact":"P Value","prefix":"nuous screening group (N = 195) ","suffix":"Age, median (range) 35.7(9–64) 3"}]}]}
>```
>%%
>*%%PREFIX%%nuous screening group (N = 195)%%HIGHLIGHT%% ==P Value== %%POSTFIX%%Age, median (range) 35.7(9–64) 3*
>%%LINK%%[[#^1pvizji1c2m|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1pvizji1c2m


>%%
>```annotation-json
>{"created":"2022-08-29T02:56:48.903Z","updated":"2022-08-29T02:56:48.903Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":21887,"end":22069},{"type":"TextQuoteSelector","exact":"Consistent with published data, the resistance rate totigecycline in our study was low, at 0%, and tigecyclinewas also used as the first-line antibiotic for CRE infectionin our study","prefix":"revention andcontrol of CRE BSI.","suffix":" [2, 25, 26]. Clinical signs of "}]}]}
>```
>%%
>*%%PREFIX%%revention andcontrol of CRE BSI.%%HIGHLIGHT%% ==Consistent with published data, the resistance rate totigecycline in our study was low, at 0%, and tigecyclinewas also used as the first-line antibiotic for CRE infectionin our study== %%POSTFIX%%[2, 25, 26]. Clinical signs of*
>%%LINK%%[[#^lmd3uqkxv5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lmd3uqkxv5


>%%
>```annotation-json
>{"created":"2022-08-29T02:57:13.089Z","updated":"2022-08-29T02:57:13.089Z","document":{"title":"13756_2020_Article_706.pdf","link":[{"href":"urn:x-pdf:bc74dc92166080a1e35bb36f5b0b4e82"},{"href":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf"}],"documentFingerprint":"bc74dc92166080a1e35bb36f5b0b4e82"},"uri":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/13756_2020_Article_706.pdf","selector":[{"type":"TextPositionSelector","start":24345,"end":24513},{"type":"TextQuoteSelector","exact":"In summary, for patients who undergo HSCT, regularcontinuous screening for CRE colonization is necessaryto assist in the early detection and management of CREcolonizers","prefix":"tion in HSCT patients.Conclusion","suffix":", including contact precaution a"}]}]}
>```
>%%
>*%%PREFIX%%tion in HSCT patients.Conclusion%%HIGHLIGHT%% ==In summary, for patients who undergo HSCT, regularcontinuous screening for CRE colonization is necessaryto assist in the early detection and management of CREcolonizers== %%POSTFIX%%, including contact precaution a*
>%%LINK%%[[#^o9pszc2h03o|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^o9pszc2h03o
